Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use

Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use

Darolutamide, a second-generation androgen receptor inhibitor (SGARI), has been shown to increase metastasis-free survival and overall survival among men with non-metastatic castration-resistant prostate cancer (nmCRPC). Its unique chemical structure potentially provides efficacy and safety advantag...

Full description

Bibliographic Details
Main Authors: Cheng-Kuang Yang, Tai-Lung Cha, Yen-Hwa Chang, Shu-Pin Huang, Jen-Tai Lin, Shian-Shiang Wang, Chao-Yuan Huang, See-Tong Pang
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Journal of the Formosan Medical Association
Subjects:
Apalutamide
Castration-resistant prostate cancer
Darolutamide
Enzalutamide
Second-generation androgen receptor inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664622004478

Internet

http://www.sciencedirect.com/science/article/pii/S0929664622004478

Similar Items